Mydecine's bought-deal financing is upsized by 50% to CAD $15 million.
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
MindMed's new Chief Development Officer has over a decade of experience leading drug development programs.
Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units
Mydecine announces a bought-deal financing with units priced at CAD$0.50.
Novamind Expands Psychedelic Medicine Access in Utah
Novamind Inc announces the expansion and optimization of its Cedar Psychiatry clinic in Utah.
Core One Labs Announces Breakthrough in Solving Psilocybin Dosing Problems by Introducing Biosynthetic Psilocybin to its Patented Thinstrip Delivery Method
Core One Labs announces a research breakthrough to help improve consistency in psilocybin dosing.
Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition
Cybin announces the API synthesis of multiple tryptamine derivatives.
MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers
MindMed commences LSD microdosing study on various health-and-wellness benefits.
ATAI or MindMed: Which Is The Better Opportunity?
ATAI Life Sciences and MindMed Inc have the deepest psychedelics operations in this sector. Which is the better opportunity?
KCSA Strategic Communications to Host Inaugural KCSA Psychedelics Investor Conference on January 26-27, 2021
KCSA Communications hosts an investment conference featuring Rick Doblin (MAPS) as a keynote speaker.
MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet High Investor Demand
MindMed closes on a CAD$92.1 million financing from what was originally a $50 million offering. Total cash on hand increases to US$144.4 million.
Will ATAI IPO Be The First Major Psychedelics Catalyst For 2021?
The ATAI Life Sciences IPO could come as soon as the end of January. What does this mean for psychedelic stock investors?
Numinus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic Products
Numinus announces a product development agreement with Optimi Health Corp.
